These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

702 related items for PubMed ID: 20399042

  • 21. Serum 25-hydroxyvitamin D, parathyroid hormone, calcium intake, and bone mineral density in Spanish adults.
    Olmos JM, Hernández JL, García-Velasco P, Martínez J, Llorca J, González-Macías J.
    Osteoporos Int; 2016 Jan; 27(1):105-13. PubMed ID: 26134682
    [Abstract] [Full Text] [Related]

  • 22. High prevalence of low vitamin D and musculoskeletal complaints in women with breast cancer.
    Napoli N, Vattikuti S, Ma C, Rastelli A, Rayani A, Donepudi R, Asadfard M, Yarramaneni J, Ellis M, Armamento-Villareal R.
    Breast J; 2010 Jan; 16(6):609-16. PubMed ID: 21070438
    [Abstract] [Full Text] [Related]

  • 23. The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis.
    Deane A, Constancio L, Fogelman I, Hampson G.
    BMC Musculoskelet Disord; 2007 Jan 10; 8():3. PubMed ID: 17214897
    [Abstract] [Full Text] [Related]

  • 24. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial.
    Rastelli AL, Taylor ME, Gao F, Armamento-Villareal R, Jamalabadi-Majidi S, Napoli N, Ellis MJ.
    Breast Cancer Res Treat; 2011 Aug 10; 129(1):107-16. PubMed ID: 21691817
    [Abstract] [Full Text] [Related]

  • 25. Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole.
    Singh S, Cuzick J, Mesher D, Richmond B, Howell A.
    Breast Cancer Res Treat; 2012 Apr 10; 132(2):625-9. PubMed ID: 22198469
    [Abstract] [Full Text] [Related]

  • 26. Baseline bone health status in multi-ethnic South African postmenopausal breast cancer patients at initiation of aromatase inhibitor therapy: A descriptive study.
    Baatjes KJ, Kotze MJ, McCaul M, Conradie M.
    PLoS One; 2019 Apr 10; 14(4):e0214153. PubMed ID: 30939140
    [Abstract] [Full Text] [Related]

  • 27. Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women.
    Ishijima M, Sakamoto Y, Yamanaka M, Tokita A, Kitahara K, Kaneko H, Kurosawa H.
    Calcif Tissue Int; 2009 Nov 10; 85(5):398-404. PubMed ID: 19795092
    [Abstract] [Full Text] [Related]

  • 28. Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.
    Lee SA, Hwang SH, Ahn SG, Lee HM, Jeong J, Lee HD.
    Breast Cancer Res Treat; 2011 Dec 10; 130(3):863-70. PubMed ID: 21861101
    [Abstract] [Full Text] [Related]

  • 29. [A prospective study of bone loss in early stage postmenopausal breast cancer treated with aromatase inhibitors].
    Sun J, Wang Q, Wang L, Gui L, Li Q, Luo Y, Zhang S, Zhang P.
    Zhonghua Zhong Liu Za Zhi; 2020 May 23; 42(5):403-407. PubMed ID: 32482030
    [Abstract] [Full Text] [Related]

  • 30. Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study.
    Prieto-Alhambra D, Servitja S, Javaid MK, Garrigós L, Arden NK, Cooper C, Albanell J, Tusquets I, Diez-Perez A, Nogues X.
    Breast Cancer Res Treat; 2012 Jun 23; 133(3):1159-67. PubMed ID: 22434523
    [Abstract] [Full Text] [Related]

  • 31. Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors.
    Bouvard B, Chatelais J, Soulié P, Hoppé E, Saulnier P, Capitain O, Mege M, Mesgouez-Nebout N, Jadaud E, Abadie-Lacourtoisie S, Campone M, Legrand E.
    Eur J Cancer; 2018 Sep 23; 101():87-94. PubMed ID: 30036740
    [Abstract] [Full Text] [Related]

  • 32. The levels of bone turnover markers 25(OH)D and PTH and their relationship with bone mineral density in postmenopausal women in a suburban district in China.
    Gao C, Qiao J, Li SS, Yu WJ, He JW, Fu WZ, Zhang ZL.
    Osteoporos Int; 2017 Jan 23; 28(1):211-218. PubMed ID: 27468899
    [Abstract] [Full Text] [Related]

  • 33. TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort.
    María RS, Marta PM, Sonia S, Natalia GG, Tamara M, Ignasi T, Maria MG, Jaime RM, Adolfo DP, Joan A, Xavier N.
    Bone; 2016 Nov 23; 92():1-8. PubMed ID: 27519968
    [Abstract] [Full Text] [Related]

  • 34. Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials.
    Nakatsukasa K, Koyama H, Ouchi Y, Sakaguchi K, Fujita Y, Matsuda T, Kato M, Konishi E, Taguchi T.
    J Bone Miner Metab; 2019 Sep 23; 37(5):864-870. PubMed ID: 30868270
    [Abstract] [Full Text] [Related]

  • 35. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
    Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, Barlow D, Makris A, Eastell R.
    J Clin Oncol; 2010 Feb 20; 28(6):967-75. PubMed ID: 20065185
    [Abstract] [Full Text] [Related]

  • 36. Treatment of Vitamin D Insufficiency in Postmenopausal Women: A Randomized Clinical Trial.
    Hansen KE, Johnson RE, Chambers KR, Johnson MG, Lemon CC, Vo TN, Marvdashti S.
    JAMA Intern Med; 2015 Oct 20; 175(10):1612-21. PubMed ID: 26237520
    [Abstract] [Full Text] [Related]

  • 37. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
    Majithia N, Atherton PJ, Lafky JM, Wagner-Johnston N, Olson J, Dakhil SR, Perez EA, Loprinzi CL, Hines SL.
    Support Care Cancer; 2016 Mar 20; 24(3):1219-26. PubMed ID: 26298334
    [Abstract] [Full Text] [Related]

  • 38. Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study.
    Pedersini R, Monteverdi S, Mazziotti G, Amoroso V, Roca E, Maffezzoni F, Vassalli L, Rodella F, Formenti AM, Frara S, Maroldi R, Berruti A, Simoncini E, Giustina A.
    Bone; 2017 Apr 20; 97():147-152. PubMed ID: 28104509
    [Abstract] [Full Text] [Related]

  • 39. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
    Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, Deleu I, Miller J, Schenk N, Neven P.
    Clin Breast Cancer; 2012 Feb 20; 12(1):40-8. PubMed ID: 22014381
    [Abstract] [Full Text] [Related]

  • 40. Prevalence and seasonal variation of hypovitaminosis D and its relationship to bone metabolism in community dwelling postmenopausal Hungarian women.
    Bhattoa HP, Bettembuk P, Ganacharya S, Balogh A.
    Osteoporos Int; 2004 Jun 20; 15(6):447-51. PubMed ID: 15205715
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 36.